Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
about
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group.Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET.Nuclear medicine techniques in Merkel cell carcinoma: A case report and review of the literature.Pancreatic neuroendocrine tumor with metastasis to the spleen: a case report.Uptake Difference by Somatostatin Receptors in a Patient with Neuroendocrine Tumor: 99mTc-Octreotide Uptake in the Lung without Uptake in Liver LesionsPharmacotherapy of Zollinger-Ellison syndrome.Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes.Pancreatic neuroendocrine neoplasms: diagnosis and management.Nuclear medicine in NET.Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis.Neuroendocrine tumours: the role of imaging for diagnosis and therapy.Review article: the investigation and management of rectal neuroendocrine tumours.Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.Quantitative SPECT/CT Imaging of (177)Lu with In Vivo Validation in Patients Undergoing Peptide Receptor Radionuclide Therapy.Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors.THERANOSTICS-clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasms.⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma.Software-assisted dosimetry in peptide receptor radionuclide therapy with 177Lutetium-DOTATATE for various imaging scenarios.Peptide receptor imaging in neuroendocrine tumors: comparison between diagnostic scintigraphy and post-therapy whole-body scan.Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature.Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines.[Pancreatic neuroendocrine neoplasms].Theranostics: radionuclide imaging and therapy in neuroendocrine tumours.
P2860
Q33435622-AD924802-EF5D-4B3F-B704-BA2B94D13711Q33841547-1D15D09A-CC3B-45EF-950A-F8D71F9E6E9FQ34157391-6340EB24-48D7-4E01-9218-111EC971E568Q34283282-384A8DD5-80D9-48BD-B42A-2DDC9B39FEB3Q34446086-5A02F409-64F3-4CF6-95A9-E603788C0BC0Q35264584-B6EEB809-AA19-49B8-BE51-D30CF9EF38C5Q35944420-E7530958-1B65-40FD-83FB-6A6E4A6BE0D8Q36244683-74DD0E0E-4360-4F58-8C7B-E2450BFE5300Q36556526-6B94FF70-450F-4607-B383-C0BBC2772D7FQ36632665-29A77C83-DBB1-4E7A-B14E-E60E1F31DBD3Q36788491-27C8106D-18EC-4CC0-A1EC-C684FA5E5038Q38019458-04717AB2-905F-41B4-951E-E8854D167D73Q38027393-BA87D9A3-8ADE-43B2-A065-97415F776FA5Q38127505-FEB4FFBC-1C27-4A5A-8FC2-B1A71A98DD2DQ38169928-2BAF7664-D284-48D9-AAD4-9A1CE7C3AADDQ38865549-067BD2C2-65C7-455E-AD25-B6CAB7AF7B38Q39016753-F3F9B259-ED18-4B12-84AE-BEB48488D7A4Q39084045-2415B629-8221-4067-A19D-593EEC051001Q39338039-45131E67-1EB4-4BBB-AC8A-E8B0F93C3120Q42345704-8DD939E3-7573-4E19-B9D9-3F8C43238E0BQ42548064-EA2D2AFE-1423-43E1-8A6B-8B2BEA83911FQ42948659-61E9384D-D9D7-4F6C-BED1-1D09BD2E4C80Q44209015-E39A7618-4D15-4C76-9F93-3854DE7E33B8Q47163935-512C3A07-3023-4AE5-BAB3-CEF333BD4ACBQ51000146-3C77E48F-D348-4E97-845E-0170E09F2E8FQ51397534-F57E8D05-FD68-44BA-A886-ABDD511B8C5BQ52717640-5FA1EC44-6A1E-4EAA-A27F-23FC1467D53FQ52984190-DD5E71FE-50BE-41E0-A811-28BABE6EE277Q54191380-C4E65990-2B2F-4E92-A83E-457CF222BC19
P2860
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
@en
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
@nl
type
label
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
@en
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
@nl
prefLabel
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
@en
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
@nl
P2093
P356
P1476
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
@en
P2093
Dik J Kwekkeboom
Eric P Krenning
Jaap J M Teunissen
P304
P356
10.1530/ERC-10-0282
P478
18 Suppl 1
P577
2011-10-17T00:00:00Z